Dear Friends and Colleagues,

Following the success of the World Congresses on Controversies in Multiple Myeloma (COMy), we are honored to invite you to COMy Multiple Myeloma Highlights 2017, a post-IMW summary congress to be held in Paris, France on April 21-22, 2017.

The congress will bring to the forefront the most innovative technologies with the latest information in the field of multiple myeloma, providing a unique opportunity for world-class leaders in the field to debate vital and contentious issues in myeloma. This thought-provoking academic dialogue will address the most challenging current clinical and therapeutic questions.

The meeting will be a wonderful opportunity to discuss the data presented during the IMW17 meeting in India”. The distinctive format of the COMy program will provide ample time for discussion, and participants are encouraged to take a proactive role in this academic dialogue. These stimulating debates will provide clinicians with state-of-theart recommendations regarding patient care.

We invite you to join us for this unique and exciting event in the beautiful and vibrant city of Paris.


Congress Chairpersons
Mohamad Mohty, France
Arnon Nagler, Israel
Thierry Facon, France
Pictures from COMy 2017
Program Highlights
  • IMW 2017 key summaries and presentations

  • Myeloma: The search for a cure?

  • Biology and diagnosis

  • Bone disease

  • Treatment of younger myeloma patients

  • Maintenance and consolidation after transplantation

  • Biology of the disease

  • MRD in routine practice

  • Auto-transplant for elderly, but fit patients

  • Clinical case discussions: Young, elderly, relapsed and high-risk myeloma cases

  • Treatment of elderly myeloma patients

  • Treatment of relapsed myeloma

  • Management of side effects

  • New drug developments

  • Management of high risk disease

  • Role of imaging techniques

  • Sequencing of therapy

  • One or 2 auto-transplant: when and for whom?

Personal Invitation to COMy 2017


For any questions please contact the Congress secretariat at

Success! Message received.